BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 16340936)

  • 21. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ; Jacobson DR
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease.
    Nissenson AR
    Am J Kidney Dis; 2001 Dec; 38(6):1390-7. PubMed ID: 11728981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S; Boulton H; Gokal R
    J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study.
    Akizawa T; Gejyo F; Nishi S; Iino Y; Watanabe Y; Suzuki M; Saito A; Akiba T; Hirakata H; Fukuhara S; Morita S; Hiroe M; Hada Y; Suzuki M; Akaishi M; Iwasaki M; Tsubakihara Y;
    Ther Apher Dial; 2011 Oct; 15(5):431-40. PubMed ID: 21974695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
    Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC;
    Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel erythropoiesis-stimulating agents: a new era in anemia management.
    Macdougall IC
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):200-7. PubMed ID: 18077782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anemia and chronic heart failure implications and treatment options.
    Anand IS
    J Am Coll Cardiol; 2008 Aug; 52(7):501-11. PubMed ID: 18687241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration.
    Toto RD; Pichette V; Navarro J; Brenner R; Carroll W; Liu W; Roger S
    Am J Nephrol; 2004; 24(4):453-60. PubMed ID: 15331889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
    Nurko S; Spirko R; Law A; Dennis VW
    Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conversion from epoetin alfa to darbepoetin alfa within the Manitoba Renal Program: evaluation of dose ratios.
    Raymond CB; Wazny LD; Vercaigne LM; Lesperance EM; Skwarchuk DE; Bernstein KN
    CANNT J; 2008; 18(1):39-43. PubMed ID: 18435363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase III clinical trials with darbepoetin: implications for clinicians.
    Glaspy J
    Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis.
    Doshi S; Chow A; Pérez Ruixo JJ
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):75S-90S. PubMed ID: 20881221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Characteristics of anaemia treatment in children with chronic kidney disease].
    Puretić Z
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():27-32. PubMed ID: 20235352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diabetes, anemia and CKD: Why TREAT?
    Singh AK
    Curr Diab Rep; 2010 Aug; 10(4):291-6. PubMed ID: 20544312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Change in darbepoetin alfa administration schedule affects erythropoiesis-stimulating agent resistance in patients with chronic kidney disease receiving hemodialysis.
    Molina M; Navarro MJ; de Gracia C; Alvarez G; de Alarcon R; Garcia MA
    Ren Fail; 2008; 30(8):778-83. PubMed ID: 18791951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia.
    Baldamus C; Krivoshiev S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A
    Adv Ther; 2008 Nov; 25(11):1215-28. PubMed ID: 18931828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS; Rocconi RP; Kilgore LC; Barnes MN
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Probabilistic cost-minimisation analysis of darbepoetin alpha versus epoetin alpha in treating anaemia secondary to chronic renal failure. Assessment in Spanish clinical practice.
    Sanz-Granda A
    Farm Hosp; 2009; 33(4):208-16. PubMed ID: 19712609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.